Transforming Imaging Data into Pathological Insights: The Role of AI in Mammographic Risk Assessment and Tumor Biology Understanding - Top-Institutions - MDSpire

Transforming Imaging Data into Pathological Insights: The Role of AI in Mammographic Risk Assessment and Tumor Biology Understanding

  • By

  • Zi Zhang

  • Jafer Elabeid

  • Thowaiba Ali

  • Jennifer Pantleo

  • Nelda Gonzalez

  • Chirag Parghi

  • April 21, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Breast Imaging
    • Oncology
    • Artificial Intelligence
    • Pathology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Oncology
    • Radiology
    • Artificial Intelligence

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Radiology
    • Artificial Intelligence
    • Breast Cancer Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Breast Imaging
    • Artificial Intelligence
    • Oncology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Radiology
    • Artificial Intelligence
    • Breast Cancer Research

Original Source(s)

Transforming Imaging Data into Pathological Insights: The Role of AI in Mammographic Risk Assessment and Tumor Biology Understanding

  • by Zi Zhang, Jafer Elabeid, Thowaiba Ali, Jennifer Pantleo, Nelda Gonzalez, Chirag Parghi

  • April 21, 2026

Related Content

Errors in Abstract and Table 1

  • May 15, 2026

Management of toxicities from antibody – drug conjugates in breast cancer

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence